Skip to main content

Table 2 Univariate and multivariate analyses of overall survival

From: Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

  Univariate Multivariate
  P value OR (95% CI) P value
Menopausal status    
Postmenopausal
Premenopausal
0.52 - -
ER status    
   Positive 0.26 - -
   Negative    
PR status    
   Negative 0.47 - -
   Positive    
HER2 status    
   Negative 0.30 - -
   Positive    
Metastatic site    
   Bone 0.01 1 0.04
Visceral   2.6 (1.0-6.8) 0.05
Both   3.2 (1.3-8.2) 0.01
Number of metastatic sites    
One site
Multiple sites
0.01 Not significant -
Disease-free interval    
   ≤12 months 0.12 - -
   >12 months    
CTC positivity    
   <5 cells 0.00 1 <0.01
   ≥5 cells   2.7 (1.6-4.2)a  
Subtype    
   'Luminal' 0.09 1 0.02
   HER2-positive   0.9 (0.4-2.0) 0.84
   Triple-negative   2.1 (1.2-3.8) 0.00
  1. aBased on cutoff level of one circulating tumor cell (CTC): 2.06 (1.16-3.68), P < 0.05. CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; PR, progesterone receptor.